The 6- and 12-month MMR was significantly higher with flumatinib vs. imatinib (33.7% vs. 18.3%; 52.6% vs. 39.6%).AEs (edema, pain in extremities, rash, neutropenia, anemia, and hypophosphatemia) were more frequent in imatinib group; diarrhea and ALT elevation were more frequent in flumatinib group. This evidence concerns the gene GPT and anemia.